158 related articles for article (PubMed ID: 18288134)
41. Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib.
Neumann F; Teutsch N; Kliszewski S; Bork S; Steidl U; Brors B; Schimkus N; Roes N; Germing U; Hildebrandt B; Royer-Pokora B; Eils R; Gattermann N; Haas R; Kronenwett R
Leukemia; 2005 Mar; 19(3):458-60. PubMed ID: 15618956
[No Abstract] [Full Text] [Related]
42. The Philadelphia translocation and pre-existing myeloproliferative disorders.
Curtin NJ; Campbell PJ; Green AR
Br J Haematol; 2005 Mar; 128(5):734-6. PubMed ID: 15725099
[No Abstract] [Full Text] [Related]
43. Alterations of NFIA in chronic malignant myeloid diseases.
Bernard F; Gelsi-Boyer V; Murati A; Giraudier S; Trouplin V; Adélaïde J; Rey J; Olschwang S; Vainchenker W; Chaffanet M; Vey N; Mozziconacci MJ; Birnbaum D
Leukemia; 2009 Mar; 23(3):583-5. PubMed ID: 18754024
[No Abstract] [Full Text] [Related]
44. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Drummond MW; Holyoake TL
Cancer; 2003 Oct; 98(8):1776-7; author reply 1777-8. PubMed ID: 14534900
[No Abstract] [Full Text] [Related]
45. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
von Bubnoff N; Peschel C; Duyster J
Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
[TBL] [Abstract][Full Text] [Related]
46. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
47. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
James C
Hematology Am Soc Hematol Educ Program; 2008; ():69-75. PubMed ID: 19074061
[TBL] [Abstract][Full Text] [Related]
48. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
49. Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene.
Janssen JJ; Hochhaus A; van Oostveen JW; Waisfisz Q; Schuurhuis GJ; Ossenkoppele GJ
Leukemia; 2004 May; 18(5):1020-1. PubMed ID: 15014529
[No Abstract] [Full Text] [Related]
50. Roots of clinical resistance to STI-571 cancer therapy.
Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
[No Abstract] [Full Text] [Related]
51. Good clinical practice in chronic myeloid leukemia: advances and prospects at the Institute of Oncology of Moldova.
Musteata V
J BUON; 2010; 15(1):188-9. PubMed ID: 20414949
[No Abstract] [Full Text] [Related]
52. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
53. Comment on: JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.
Tsilimidos G; Blum S
Ann Hematol; 2023 Sep; 102(9):2619-2620. PubMed ID: 37256305
[No Abstract] [Full Text] [Related]
54. JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.
Tosoni L; Fabbro D; Pizzano U; Mullai R; Morelli G; Franzoni A; Damante G; Toffoletti E; Damiani D; Fanin R; Tiribelli M
Ann Hematol; 2023 May; 102(5):1279-1280. PubMed ID: 36947213
[No Abstract] [Full Text] [Related]
55. Transformation of polycythemia vera to chronic myelogenous leukemia.
Mirza I; Frantz C; Clarke G; Voth AJ; Turner R
Arch Pathol Lab Med; 2007 Nov; 131(11):1719-24. PubMed ID: 17979493
[TBL] [Abstract][Full Text] [Related]
56. Insights into JAK2-V617F mutation in CML.
Bocchia M; Vannucchi AM; Gozzetti A; Guglielmelli P; Poli G; Crupi R; Defina M; Bosi A; Francesco L
Lancet Oncol; 2007 Oct; 8(10):864-6. PubMed ID: 17913657
[No Abstract] [Full Text] [Related]
57. GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia.
Rinaldi CR; Martinelli V; Rinaldi P; Ciancia R; del Vecchio L
Leuk Lymphoma; 2008 Jul; 49(7):1416-9. PubMed ID: 18452096
[No Abstract] [Full Text] [Related]
58. Insights into JAK2-V617F mutation in CML.
Büsche G; Hussein K; Bock O; Kreipe H
Lancet Oncol; 2007 Oct; 8(10):863-4. PubMed ID: 17913656
[No Abstract] [Full Text] [Related]
59. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.
de Conchon MRM; Costa JL; Novaes MMY; Dorlhiac-Llacer PE; de Alencar Fischer Chamone D; Bendit I
Int J Hematol; 2008 Sep; 88(2):243-245. PubMed ID: 18626727
[No Abstract] [Full Text] [Related]
60. Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia.
Inami M; Yamaguchi H; Hasegawa S; Mitamura Y; Kosaka F; Kobayashi A; Kimura S; Dan K; Inokuchi K
Leukemia; 2008 Jan; 22(1):216. PubMed ID: 17851549
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
